CTI BioPharma Announces Publication of Article Highlighting Pacritinib Data from the PAC203 Phase 2 Study in Myelofibrosis in Blood Advances
SEATTLE, Nov. 30, 2020 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances. The article, titled “Determining the Recommended Dose of Pacritinib: Results from the PAC203 Phase 2 Dose-Finding Study…
Comments Off on CTI BioPharma Announces Publication of Article Highlighting Pacritinib Data from the PAC203 Phase 2 Study in Myelofibrosis in Blood Advances